Literature DB >> 33343172

Co-infection with Malaria and Coronavirus Disease-2019.

Manjusha Ray1, Archana Vazifdar1, Shashikala Shivaprakash2.   

Abstract

Entities:  

Year:  2020        PMID: 33343172      PMCID: PMC7733433          DOI: 10.4103/jgid.jgid_160_20

Source DB:  PubMed          Journal:  J Glob Infect Dis        ISSN: 0974-777X


× No keyword cloud information.
Sir, Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), is an ongoing global pandemic. Among the plethora of knowledge being garnered about the virus, the occurrence of co-infections and superinfections is also being reported.[1] Although SARS-CoV-2 is the first culprit to be suspected in symptomatic cases, it is important not to lose sight of the burden India faces with other infectious diseases. We report a case of malaria and COVID-19 co-infection. A 67-year-old male, a known case of type 2 diabetes mellitus and heart disease, presented with complaints of fever and progressive exertional breathlessness for 4 days in the 1st week of May. He had no history of travel or contact with a COVID-19-confirmed case. On examination, his oxygen saturation was 96% on room air. Complete blood count revealed moderate thrombocytopenia of 71.0 × 109/L with normal hemoglobin and white blood cell counts. On peripheral blood examination, ring forms and trophozoites of Plasmodium vivax were seen, along with reactive lymphocytes [Figure 1]. Chest X-ray (anteroposterior view) showed haziness in both lung fields. The patient was started on intravenous injection artesunate, followed by artemether and lumefantrine, per oral. He responded well to the antimalarial treatment with symptomatic relief.
Figure 1

Peripheral blood smear showing ring form (red arrow) and trophozoite (white arrow) of Plasmodium vivax. A reactive lymphocyte is also seen (black arrow) (Leishman stain, ×400)

Peripheral blood smear showing ring form (red arrow) and trophozoite (white arrow) of Plasmodium vivax. A reactive lymphocyte is also seen (black arrow) (Leishman stain, ×400) Although his first nasopharyngeal swab for SARS-CoV-2 real-time reverse transcription–polymerase chain reaction test indicated the absence of the virus, repeat swabs sent on day 3 revealed positivity for the same. In the coming week, his platelet counts improved to normal levels, and he became clinically asymptomatic and stable. Co-infections of COVID-19 are thought to be very common, as high as 80%, most commonly with seasonal respiratory pathogens.[1] With overlapping symptoms and travel history (significant for COVID-19 and malaria), co-infection diagnosis may be challenging. India witnesses a temporal rise in water-borne and water-related diseases, including malaria, in the monsoon season, annually. With the ongoing pandemic, one can expect an increase in the rate of co-infections with COVID-19. It is important to investigate thoroughly in order to correctly identify a treatable infection as well as the presence of co-infections. While many clinical trials are ongoing for COVID-19 with no approved treatment regimen yet, there are already established antimalarial, antiviral, and antibiotic schemes for known infections. At present, the entire population, globally, is at very high risk of COVID-19. In 2018, it was reported that nearly half of the world population was at risk of malaria.[2] A single case of COVID-19 can potentially be infective to 3.58 susceptible individuals.[3] Likewise, an untreated case of malaria can lead to community spread. Furthermore, due to lockdowns and restricted mobility, there have been interruptions to health-care access and national malarial control programs. The World Health Organization is urging countries to ensure the continuity of malaria services in the context of the COVID-19 pandemic.[4] It is advisable that health-care professionals screen for malaria while they test for COVID-19.[5] This would help in timely identification of two infectious diseases having significant global impacts and reduce unnecessary morbidity and mortality.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  2 in total

1.  COVID-19 and malaria: A symptom screening challenge for malaria endemic countries.

Authors:  Pascalina Chanda-Kapata; Nathan Kapata; Alimuddin Zumla
Journal:  Int J Infect Dis       Date:  2020-04-27       Impact factor: 3.623

2.  A mathematical model for simulating the phase-based transmissibility of a novel coronavirus.

Authors:  Tian-Mu Chen; Jia Rui; Qiu-Peng Wang; Ze-Yu Zhao; Jing-An Cui; Ling Yin
Journal:  Infect Dis Poverty       Date:  2020-02-28       Impact factor: 4.520

  2 in total
  9 in total

1.  Prolonged fever and exaggerated hypercoagulopathy in malaria vivax relapse and COVID-19 co-infection: a case report.

Authors:  Tri Pudy Asmarawati; Okla Sekar Martani; Bramantono Bramantono; Muhammad Vitanata Arfijanto
Journal:  Malar J       Date:  2022-06-23       Impact factor: 3.469

Review 2.  Coronavirus Disease-2019 (COVID-19) and the Liver.

Authors:  Anshuman Elhence; Manas Vaishnav; Sagnik Biswas; Ashish Chauhan; Abhinav Anand
Journal:  J Clin Transl Hepatol       Date:  2021-03-22

3.  Insights into Plasmodium and SARS-CoV-2 co-infection driven neurological manifestations.

Authors:  Omkar Indari; Budhadev Baral; Kartik Muduli; Ambika Prasad Mohanty; Natabar Swain; Nirmal Kumar Mohakud; Hem Chandra Jha
Journal:  Biosaf Health       Date:  2021-04-30

4.  Clinical characteristics, complications, and predictors of outcome of hospitalized adult Sudanese patients with COVID-19 and malaria coinfection in Sudan: A multicenter retrospective cross-sectional study.

Authors:  Khabab Abbasher Hussien Mohamed Ahmed; Elfatih A Hasabo; Mazin S Haroun; Moh Mah Fadelallah Eljack; Esraa Hassan Salih; Yousif F O Altayeb; Alshareef B Nour; Abdallah M Abdallah; Waddah A M Osman; Mohammed Y E Yousif
Journal:  J Med Virol       Date:  2022-04-21       Impact factor: 20.693

5.  Co-Infection with Plasmodium vivax and COVID-19 in Thailand.

Authors:  Parat Boonyarangka; Kittijarankon Phontham; Sabaithip Sriwichai; Kamonporn Poramathikul; Krit Harncharoenkul; Worachet Kuntawunginn; Napat Maneesrikhum; Sarayouth Srisawath; Chanida Seenuan; Chattakorn Thanyakait; Kanjana Inkabajan; Suda Pludpiem; Kingkan Pidtana; Samandra Demons; Brian Vesely; Mariusz Wojnarski; John S Griesenbeck; Michele Spring
Journal:  Trop Med Infect Dis       Date:  2022-07-22

6.  MIS-C and co-infection with P. vivax and P. falciparum in a child: a clinical conundrum.

Authors:  Michela Scalisi; Salvatore Giordano; Laura Antonella Canduscio; Maria Concetta Failla; Luca Messina; Elisa Sferrazza; Raffaella Rubino; Lucia Siracusa; Veronica Vanella; Antonio Cascio; Claudia Colomba
Journal:  Ital J Pediatr       Date:  2022-07-27       Impact factor: 3.288

7.  A report on incidence of COVID-19 among febrile patients attending a malaria clinic.

Authors:  Subhasish Kamal Guha; Malabika Biswas; Bishal Gupta; Alisha Acharya; Supriya Halder; Bibhuti Saha; Moytrey Chatterjee; Pratip Kumar Kundu; Ardhendu Kumar Maji
Journal:  Trop Parasitol       Date:  2021-05-14

8.  Drivers of autochthonous and imported malaria in Spain and their relationship with meteorological variables.

Authors:  Arturo Sousa; Mónica Aguilar-Alba; Mark Vetter; Leoncio García-Barrón; Julia Morales
Journal:  EuroMediterr J Environ Integr       Date:  2021-02-16

9.  Malaria amidst COVID-19 in India: Challenges, Efforts, and Recommendations.

Authors:  Anmol Mohan; Um Ul Wara; Syeda Wania Amjad; Sudhan Rackimuthu; Reem Hunain; Hiba Khan; Ana Carla Dos Santos Costa; Shoaib Ahmad; Mohammad Yasir Essar
Journal:  Clin Epidemiol Glob Health       Date:  2021-09-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.